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ABSTRACT
BACKGROUND: MDR-TB is increasing and now it has become a big threat to the National
tuberculosis program. The Ethiopian government has identified MDR-TB as one of the priority public
health problems and it is committed to initiate comprehensive treatment of MDR cases in the country.
With the approval of the Green Light committee, it has started the treatment of MDR-TB since February
2009 by selecting a pilot project which is at the St. Peter’s TB Specialized hospital in Addis Ababa and
rapid expansion to the regions is foreseen and preparation is underway.  In this study we will assess the
time to sputum smear and culture conversion.
OBJECTIVE: To assess the time to sputum smear and culture conversion and determinant factors
associated with conversion among MDR-TB patients admitted to St. Peter’s TB-specialized hospital.
METHOD: Retrospective Cross sectional study among MDR-TB patients admitted to St. Peter’s TB-
specialized hospital starting from February 2009. A total of 149 patients who fulfill the inclusion criteria
are included in the study. Data were collected using compilation form from the available medical records,
treatment charts, bacteriologic reports and chest x-ray results.
RESULTS: Sputum smear conversion was found to be 107(71.81%), 133(89.26%) in the first and
second month respectively.  Age was found to be significantly associated with sputum conversion P:
0.032, and 0.027. The Culture conversion in the second month revealed 73(48.99%).  HIV status,
presence of pleural effusion were factors found to be associated with culture conversion at 2 months, HIV
positives and those with pleural effusion being late converters.  Culture conversion in the third month
revealed 123(82.55%) and here those age group ≤ 24 and HIV negatives were found to covert early
CONCLUSION AND RECOMMENDATION This study revealed that with strict in-patient treatment,
of nearly 80% of sputum smear and culture conversion could be achieved. This can reduce the length of
in-patient stay (which at present is extending up to six months) and more patients can get chance for
MDR-TB treatment. The younger age group ≤24 years, HIV negatives and those with no pleural effusion
are the early converters therefore minimizing the length of stay in the hospital to 3 months can be
considered on these patients.
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INTRODUCTION: Tuberculosis (TB) is a major public health problem and has been recognized
throughout the world since early ages. Since 1950 control efforts have been initiated by
establishment of sanatoria and later strengthening by implementation of DOTS strategy in the
early 1990’s. Poverty, homelessness, congregate settings, alcoholism, drug abuse and HIV are
the main risk factors for TB. At present tuberculosis control strategy in Ethiopia relies on WHO
recommended stop-TB strategy and it has been implemented since 2006. (1)
The directly observed treatment short course (DOTS) strategy has important components:
government commitment to ensure sustained and comprehensive TB control activities; case
detection by sputum smear microscopy among symptomatic patients; standardized short course
chemotherapy using regimens six to eight months; regular un-interrupted supply of all essential
anti-TB drugs and laboratory supplies; and standardized recording and reporting system. (2; 3; 4)
The current threats for DOTS strategy in Ethiopia are; the detection rate remains low, at 36%,
compared with World Health Organization’s target of 70% detection. The number of TB cases is
likely to increase as Ethiopia’s Human Immune Deficiency Virus/Acquired Immune Deficiency
Syndrome (HIV/AIDS) epidemic expands. Self withdrawal from treatment, the worsening socio-
economic trends are factors for the increase of TB incidence. Following all these the other main
threat is the emergence of Multi-drug Resistant Tuberculosis (MDR-TB) and also Extensively
Drug- Resistant Tuberculosis (X-DR TB). (5)
Multi-drug Resistant Tuberculosis (MDR-TB) is defined as resistance to Ionized (INH) and
Rifampicin (RIF), the two most important first line anti-TB drugs. MDR-TB is a man-made
problem. When patients stop taking or do not take enough of the right medications, the poor
quality of anti-tuberculosis drugs supply and due to the poor follow-up of the means of
tuberculosis transmission leads to the emergence and spread of mycobacterium tuberculosis
strains resistant to multiple drugs which represent a major public health problem in a number of
countries and an obstacle to effective global TB control. In addition, new cases of extensively
drug resistant tuberculosis(X-DR) are also emerging which makes the condition even worst.
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X-DR is defined as resistance to a floroquinolone and at least one second line injectable drug
Kanamycin (Km), Amicacin (Am), Capreomycin (Cm), Streptomycin (Stm) in addition to INH
and RIF resistance. (6); (7); (1). MDR-TB is a growing problem in resource-poor settings where
adequate diagnosis and treatment are often unavailable. Sub-Saharan Africa would seem to have
all of the conditions for a “perfect-storm” of HIV infection and MDR-TB. (8)
The Ethiopian government has identified MDR-TB as one of the priority public health problems
and is committed to initiate comprehensive treatment of MDR-TB cases in the country.
Therefore, the programmatic management of MDR-TB in Ethiopia is introduced in a step-wise
manner, starting from a Green Light Committee approved  pilot project program in Ababa (St.
Peter’s Tb specialized hospital) and rapid expansion to the regions is foreseen and preparation is
underway. St. Peter’s Tb specialized hospital, has started treating MDR-TB cases starting from
February 2009. The site was selected as a pilot project for many reasons: It has a long history of
TB management; at present it is the only federal hospital specialized in TB care which has given
the staff ample experience in TB management; the setting is spacious enough to accommodate
renovation and building of new structures. The staff has also taken the initiative to treat some
patients with MDR-medication imported privately. It also has a good collaborative partnership
with the Ethiopian Health and Nutrition Research Institute (EHNRI) housing the National
Reference Laboratory (NRL). (1) During the treatment period, the MDR-TB patients are being
followed as in-patient till two consecutive culture results are reported negative. When they reach
that point in time, they are then discharged to follow the treatment at OPD level. All doses are
directly observed. (1) In this study we would like to assess the time it takes for a patient to
convert to a negative-sputum smear and negative culture result and the determinant factors
associated with conversion. This will have an impact on the duration of admission of MDR-
patient, which at present extends from three to six months. Since we are expecting that we can
obtain early conversion, it is anticipated that this will help in reducing the hospital stay of the
patients and will increase the turnover. This will enable us to give chance to a larger number of
MDR-patients to be treated. There-by we can inform policy makers and guideline developers on
the optimal time of MDR patient stay in the hospital so that they may decide to allocate the
necessary resources accordingly.
Page 3
LITRATURE REVIEW
TB EPIDEMIOLOGY (Global and local)
Tuberculosis is a preventable and curable disease, but remains as the biggest public health
problem and a leading cause of morbidity and mortality in the world. One third of the world’s
population is estimated to be infected with tubercle bacilli and hence at risk of developing active
disease. Globally, in 2008, the annual incidence of TB, expressed as the number of new TB cases
was about 8.9-9.9 million people (7.4 million of these in Asia and Sub-Saharan Africa), the
annual number of deaths due to TB among HIV negative people was 1.1-1.7 million and 0.45-
0.62 million TB deaths among HIV positive people. In developing countries, TB comprises 25%
of all avoidable adult deaths. It is estimated that nearly one million (11%) of the total TB cases
are children less than 15 years of age. TB is killing nearly 5000 people every day (2-3million/yr).
The number of notified cases of TB in 2008 was 5.7 million, equivalent to 55-67% of all incident
cases. (9) ;( 10); (1)
Ethiopia is ranking seventh among the world’s 22 high-burden countries responsible for 80% of
the world’s TB burden. Ethiopia had an estimate of 314,267 TB cases, with incidence rate of 378
cases per 100,000 populations in the year 2007. (11); (12)
TB Control Strategies: The components of DOTS strategy are: government commitment to
ensure sustained and comprehensive TB control activities; case detection by sputum smear
microscopy among symptomatic patients self reporting to health facilities; standardized short
course chemotherapy using regimens six to eight months; regular, uninterrupted supply of all
essential anti-tuberculosis drugs and laboratory supplies; and standardized recording and
reporting system.(1); (2); (4)
In MDR-TB, the components of DOTS strategy are: sustained political commitment; appropriate
case-finding strategy including quality-assured culture and drug susceptibility testing (DST);
appropriate treatment strategies that use second line drugs under proper case management
conditions; uninterrupted supply quality-assured second-line anti-tuberculosis drugs; recording
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and reporting system designed for drug resistance-TB control programs that enables performance
monitoring and evaluation of treatment outcomes. (1)
Global and Local status of MDR-TB: The emergence of resistant to anti-tuberculosis drugs, and
particularly of multi-drug-resistant TB (MDR-TB), has become a major public health problem in
a number of countries and an obstacle to effective global TB-control. Nearly half a million cases
of MDR-TB emerge every year as a result of under-investment in basic activities to control TB,
poor management of supply and quality of anti-tuberculosis drugs, improper treatment of TB
patients and poor control of the transmission of the disease in congregate settings. MDR-TB can
be treated and cured but treatment regimens are complicated, lengthy and expensive.
Medications that are currently available can produce crippling side effects and are less effective
than drugs for non-resistant TB. If left untreated, however MDR-TB not only kills the patient but
can spread to other people, where it may develop additional drug resistance. In many areas such
as Africa the extent of drug-resistant is unknown and in most resource-constrained countries the
treatment of patients with MDR-TB is absent or inadequate. MDR-TB is defined as resistant to
INH and RIF, the two most important first-line anti-tuberculosis drugs. The worst was yet to
come: in 2006, extensively drug resistant TB (XDR-TB) emerged. This is defined as resistant to
first and second line drugs. This is a very serious emerging threat to global public health. (1, 6, 8)
According to WHO 2008 report, in Ethiopia, 5825 MDR-TB cases (4964 among newly
diagnosed and 861 among previously treated TB cases) were estimated to have occurred in 2006.
According to the anti-TB drug resistance survey conducted nationwide in 2005 (EHNRI/FMOH),
among 804 newly diagnosed TB cases 1.6% were found to be infected with MDR-TB. The rate
of MDR TB among specimens from 76 previously treated TB cases was 11.8%. The same survey
reported that, TB with Isoniazid mono-resistance and Rifampicin mono-resistance, among new
TB cases, was 2% and 1%, respectively. Notified prevalence of mono-resistance to INH and
Rifampicin among previously treated TB cases was 5.3% and 1.3%, respectively. (1)
Resistance to anti-tuberculosis drugs has now become a threat to national tuberculosis program
in both developed and developing countries. MDR-TB may be responsible for prolonged
shedding of bacilli. The treatment for MDR-TB is more expensive, toxic and difficult to
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administer. Therefore, the importance of patient and health care staff compliance, case finding
and resistance surveillance has to be stressed. The cost for treatment of the increasing MDR-TB
will be a greater financial burden on the already over stretched budgets of national, international
and non-governmental organizations. (3)
Treatment of MDR-TB:
For treatment of multidrug-resistant TB or TB with an isolate resistant to at least isoniazid and
rifampicin, the status of Mycobacterium cultures is generally used to guide therapy for patients
treated in either resource-limited or resource replete settings and is considered the most
important interim indicator of the efficacy of treatment for multidrug-resistant TB. (13); (14)
Treatment of patients with multidrug-resistant TB is on the basis of results of drug susceptibility
testing (DST) obtained before the treatment initiation. Each dose is given as directly observed
therapy (DOT) throughout the treatment. The duration of MDR-TB treatment is 18 to 24 months.
The intensive phase being a minimum of six months and the continuation phase 12 to 18 months.
Patients with MDR-TB confirmation but not with full DST result are treated with Ethambutol,
Pyrazinamid (Z), Kanamycin (Amicacin), Levofloxain (Lfx), Ethionamid (Eto) & Cycloserin
(Cs). MDR-TB patients susceptible to both Kanamycin and Quinolons are treated as in the first
case. MDR-TB patients susceptible to Kanamycin but resistant to Quinolons are treated with
Ethambutol, Pyrazinamid, Kanamycin/(Amicacin), Moxifloxacin, Ethionamid, Cycloserin &
Para Amino Salicylic Acid (PAS). Extensively drug resistant tuberculosis cases, that is MDR-TB
and resistant to Quinolons and Kanamycin are treated with Ethambutol, Pyrazinamid,
Capreomycin, Moxifloxacin (Mfx), Ethionamid, Cycloserin & PAS. (6)
The increasing worldwide incidence of extensively drug resistant tuberculosis (XDR-TB) has
emerged as a threat to public health and tuberculosis control. Treatment outcomes have varied
among studies, and data on long-term survival are still scarce. In a cohort retrospective study
conducted in South Korea, medical records were reviewed of patients newly diagnosed with or
retreated for MDR-TB from 2000 to 2002. The study was monitored for 3 to 7 years after the
initiation of treatment. Initial treatment outcome and cumulative survival rates were analyzed
and predictors of treatment success and survival were defined. Of 1407 patients with MDR-TB
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75 (5.3%) had XDR-TB at treatment initiation. The default rate was high (453/1407; 32%) and
patients with XDR-TB had lower treatment success (29.3 vs. 46.2%; P=0.004) and higher all
cause (49.3 vs.19.4%; P<0.001) and TB related disease mortality (41.3 vs.11.8%; P<0.001) than
other patients with MDR-TB. The presence of XDR-TB significantly affected treatment success
(odds ratio, 0.23; 95% confidence interval, 0.08-0.64; P=0.005), all cause mortality (hazards
ratio, 3.25; 95% CI, 1.91-5.53; p< 0.001), and TB related mortality (hazards ratio, 4.45; 95% CI,
2.48-8.00; P<0.001) on multivariate analyses. The study concluded that XDR-TB occurred in a
substantial proportion of patients with MDR-TB, and was the strongest predictor of treatment
outcomes and long-term survival in patients with MDR-TB. Adequate TB control policies should
be implemented to prevent the further development and spread of drug resistance. (15); (16);
(17)
A retrospective cohort study done in Latvia among civilian patients with multidrug resistant TB
treated with the DOTS-plus strategy between 1 January and 31 January 2000 showed that among
167 patients who were sputum culture-positive at initiation of second-line therapy, 129 (77%)
converted in a median time of 60 days (range, 4 to 462 days) and 38 (23%) did not convert.
Independent predictors of a longer sputum culture conversion time included previous treatment
for multi-drug resistant TB, high initial sputum culture colony count, bilateral cavitations on
chest radiography, and the number of drugs the initial isolate was resistant to at treatment
initiation. Treatment outcomes were statistically significantly worse for patients who did not
convert their sputum culture within 2 months. (18)
Little is known about treatment of multi-drug resistant tuberculosis (MDR-TB) in high HIV-
prevalence settings such as Sub-Saharan Africa. A retrospective analysis of early outcomes of
the first cohort of patients registered in the Lesotho national MDR-TB program was done
between July 21, 2007 and April 21, 2008. Seventy-six patients were included for analysis.
Patient follow-up ended when an outcome was recorded, or on October 21, 2008 for those still
on treatment. Fifty-six patients (74%) were infected with HIV; the median CD4 cell count was
184 cells/μl (range 5–824 cells/μl). By the end of the follow-up period, study patients had been
followed for a median of 252 days (range 12–451 days). Twenty-two patients (29%) had died,
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and 52 patients (68%) were alive and in treatment. In patients who did not die, culture
conversion was documented in 52/54 patients (96%). One patient had defaulted, and one patient
had transferred out. Death occurred after a median of 66 days in treatment (range 12–374 days).
The study concluded that in a region where clinicians and program managers are increasingly
confronted by drug-resistant tuberculosis, this report provides sobering evidence of the difficulty
of MDR-TB treatment in high HIV-prevalence settings, and further research is urgently needed
to improve MDR-TB treatment outcomes in high HIV-prevalence settings. (19)
Although type 2 diabetes (DM) is a recognized risk factor for development of tuberculosis (TB),
impact on treatment is unclear. Using retrospective survival analysis done in south Texas,
between 1996 and 2002 on 469 culture-positive TB patients identified that Diabetes to be an
independent risk factor for a 5-day delay in mycobacterium clearance within the first 60 days of
treatment. The association of diabetes with tuberculosis is a re-emerging problem because of the
rapid rise worldwide of type 2 diabetes. (20) ;( 21)
For patients with drug susceptible –TB, treated in resource limited settings, diagnosis is based on
the presence of acid-fast bacilli identified in sputum through evaluation with smear microscopy.
Patient management, including duration of treatment and final treatment success, is based on
conversion of sputum smears to acid-fast bacilli-negative status. (22)
Conversion of sputum Mycobacterium cultures from positive growth to negative growth of
Mycobacterium tuberculosis in patients with pulmonary tuberculosis (PTB) is considered the
most important interim indicator of the efficacy of anti-TB pharmacologic treatment for
multidrug-resistant disease. (18)
Rational of the Study: The Ethiopian government has identified MDR-TB as one of the priority
public health problems and it is committed to initiate comprehensive treatment of MDR-TB
cases in the country. The pilot program in Addis Ababa (St. Peter TB specialized hospital)
started two years back (February 2009) for the first time in the country after the approval of the
Green Light Committee. Rapid expansion to the regions is foreseen and preparation is underway.
Thus, in Ethiopia, at this point in time there is nothing to say regarding the MDR-TB treatment
outcome. (1)
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In this study we would like to assess the time it takes for a patient to convert to a negative
sputum smear and sputum culture results and the determinant factors associated with conversion.
This will help us to identify how early are MDR-TB patients having their sputum smear and
culture conversion, which in-turn will determine the duration of hospital stay of the patients.
Now the hospital stay is extending 3-6 months; which after this research is anticipated to be
minimized only to three or even less months. Therefore, we can inform policy makers and guide
line developers on the optimal time of MDR patient stay in the hospital so that they may decide
to allocate necessary resources accordingly.
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OBJECTIVE
General objective:
To assess the time of smear and culture conversion and determine factors affecting conversion
among MDR P.TB patients admitted to St. Peter TB specialized hospital Addis Ababa, Ethiopia.
Specific objective:
 To determine the time to sputum smear conversion
 To determine the time to sputum culture conversion
 To identify the determinant factors associated with sputum smear culture conversion
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METHODOLOGY
Study Design; is Retrospective Cross sectional study.
Study Area:
The study area is St. Peter’s TB Specialized hospital. It is located in Gulele Sub-city, wereda 01,
Addis Ababa. It was established in 1963 G.C. At that time, it was called TB Demonstration and
Training Centre or Sanatorium. The out-patient and the in-patient departments had separate
administrative bodies and two different campuses for a long period of time. The administrative
bodies joined together few years back and the two campuses were brought together since the
beginning of September, 2010.
St. Peter’s TB specialized hospital is the only referral hospital in the country for pulmonary
tuberculosis cases. Most of the patients that are served by the hospital are those who are critically
ill, those coming from the most rural areas and those who are poor and do not have any support.
At present the hospital has 218 administrative staff and 161 technical staff. Currently, more than
32,997 patients are being served every year. The main activities of the hospital include clinical
services, diagnostic services and research activities. Since February 2009, the hospital has started
treating MDR-TB patients as a first pilot project in Ethiopia. In the future, the hospital will serve
as a national MDR-TB referral centre in case of severe side effects and as a centre of excellence
and training during the scaling up of MDR-TB treatment to the regions.
Source population:
The source populations are all Multi-Drug Resistant Tuberculosis patients.
Study population:
All Multi-Drug Resistant Tuberculosis patients admitted and treated with second-line anti-
tuberculosis treatment in St. Peter’s TB-specialized hospital.
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Sample size
The required sample size for the study is determined using single population proportion method.
Thus we used the formula: n = Z α 2 * P (1-P)
2          d2
 n = sample size
 Z α 2 = Z-score at 95% confidence interval = 1.96
2
 P = Smear/Culture conversion rate at third month (0.88 from literature and with
observation)
 d = margin of error (0.05)
(1.96)*(1.96)* (.88)*(0.12)    = 163 is the sample size
(0.05)*(0.05)
Sampling technique
In St. Peter’s TB Specialized hospital there were 160 Multi-drug resistant patients who were
under treatment with second line Anti-TB drugs. All patients with all information needed for the
study were included.
Inclusion Criteria
All patients admitted and treated for MDR-TB at St. Peter’s TB-Specialized Hospital
Exclusion Criteria
Patients whose charts were not complete with all information needed for the study were
excluded.
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Operational Definitions
 Tuberculosis: (TB) is a bacterial disease caused by Mycobacterium tuberculosis
(occasionally by Mycobacterium bovis and Mycobacterium africanum).
 Multi-Drug Resistant Tuberculosis: (MDR-TB) is TB that is resistant at least to Isoniazid
(INH) and rifampicin (RMP), the two most powerful first-line anti-TB drugs
 Extensively Drug-Resistant Tuberculosis: (X-DR-TB) is resistant to Isoniazid (INH) and
rifampicin (RMP), plus resistant to any fluoroquinolone and at least one of the three
injectable second-line drugs (amicacin, kanamycin, capreomycin)
 Culture Conversion: is said to be achieved if the initially positive culture results were
reported negative for M. tuberculosis at any time after multidrug-resistant TB-treatment
has started.
 Sputum smear Conversion: is said to be achieved if the initially positive smear results
were reported negative for M. tuberculosis at any time after multidrug-resistant TB-
treatment has started.
 Early culture conversion: patients whose culture was positive before the initiation of
treatment, converts to negative within three months  or less after the start of treatment.
 Early sputum smear conversion: patients whose sputum smear was positive before the
initiation of treatment, converts to negative within three months  or less after the start of
treatment.
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Data collection
All important data information was collected systematically from all 160 patients treated for
MDR-TB using data compilation forms. The dependent variables: the sputum smear conversion
and also culture conversion are collected from the bacteriologic laboratory reports. The
independent variables: (the personal identifying data or the baseline demographic characteristics)
sex, age, weight, the clinical data such as previous treatment of TB, HIV-status, CD4-count,
history of diabetes, history of hypertension, the number of anti-TB drugs to which the M.
bacterium tuberculosis strain was resistant, the contact history with pulmonary tuberculosis
patient, the chest x-ray results, the place of treatment for category I and II were reviewed from
the medical records.
On admission for MDR treatment all patients had positive sputum smear and culture results.
After the initiation of anti-tuberculosis treatment, sputum smear and also culture conversion was
said to be achieved if two consecutive smear and culture results were reported negative for M.
tuberculosis. The treatment of patients with multi-drug-resistant TB is on the basis of results of
drug susceptibility testing (DST) obtained before the treatment initiation. Each dose is given as
directly observed therapy (DOT) throughout the treatment.
Ensuring data quality;
Data enumerator nurses and supervisors (physicians) were selected from St. Peter’s TB
Specialized hospital working in the MDR-TB ward and were trained for two consecutive days on
how data has to be collected. The data enumerators collected all the necessary data from the
charts and the supervisors (physicians) working in the MDR-TB ward checked the completeness
of the collected data. Finally the principal investigator exhaustively checked all the data collected
for their completeness and accuracy before submission for data entry. The charts with incomplete
data were excluded.
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Data analysis
After the data collection process was completed the collected data was double entered by the
Principal Investigator and by a data officer in Armauer Hansen Research Institute (AHRI) using
a computer soft ware EPI-info and data was cleaned. The data was exported to SPSS 16.0 and
Analysis was performed by these statistical packages and summarized by descriptive statistics
and presented with frequency tables. Categorical variables are reported as proportion along with
the 95% confidence interval. Continuous variables are reported as mean and median. Internal
comparisons were made to compare factors associated with sputum culture conversion and no
conversion using Logistic Regression. P-value less than 0.05 were considered statistically
significant. (See results on following page)
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ETHICAL CONSIDERATION
This research has no harmful effect on patients. There are no invasive procedures involved as the
data are collected from charts. All data forms are kept in secure place and the patients’ name
were not included to maintain confidentiality. The proposal was assessed by the ethical
committee at Addis Continental Institute of Public Health jointly with Gondar University and
was ethically cleared. In addition the IRB in St. Peter’s TB Specialized Hospital and AHRI have
also reviewed the proposal. Then the officials in St. Peter’s TB specialized hospital were
informed about the purpose of the research and permission was obtained to conduct the research.
Page 16
RESULTS
Socio-demographic Characteristics
Among 160 participants who were treated for MDR-TB at St. Peter’s TB-Specialized Hospital
since February 2009, 149 (93.13%) participants’ charts were included for final analysis. The
other 11(6.87%) participants (very recently admitted to hospital) were excluded because the
sputum smear conversion results as well as the culture conversion results were missing.
Among the 149(100%) participants who were included in the final analysis, 125(83.90%) were
from Addis Ababa and the rest 24(16.10%) were from other Administrative Regions. The age of
the participants’ ranges from 9 to75 years with a mean age 29.56 and ±SD 10.59 In terms of
gender distribution 79(53.00%) of the participants were female and 70(47.00%) were male.
(Table.1)
Clinical History
The weight of the participants on admission less than 40 Kg 29(19.50%), 40-50 Kg 69(46.30%),
above 50Kg 51(34.23%) (Fig1) Those participants who were previously treated with Category 1
anti-TB treatment are 146(98%) and not treated 3(2.0%). Those participants who were
previously treated with Category 2 anti-TB treatment are 145(97.3%) and not treated 4(2.7%).
participants having history of contact with pulmonary tuberculosis patient 59(39.6%), with no
history of contact with pulmonary tuberculosis patient 90(60.4%). Participants who are HIV
positive 36(24.2%), HIV negative 113(75.8%). Participants with CD4-count ≥200 cells/mm3
32(88.89%), with CD4-count ≤ 200 cells/mm3 4(11.11%). (Table1)
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Table 1
Socio-demographic and Clinical Characteristics of MDR-TB Patients treated in St.
Peter TB-Specialized Hospital Addis Ababa, Ethiopia 2011
Characteristics No %
Address
Addis Ababa 125 83.89
Other Administrative Region 24 16.11
Age group
Less than24 years 53 35.57
25-34 58 38.93
≥35 38 25.5
Sex
Female 79 53.02
Male 70 46.98
Patient Clinical history and Clinical
Characteristics
Previously Treated with Category I Anti-TB
Yes 146 97.99
No 3 2.01
Previously Treated with Category II Anti-TB Rx
Yes 145 97.32
No 4 2.68
Previous History of Contact with PTB-patient
Yes 59 39.6
No 90 60.40
HIV Status
Positive 36 24.16
Negative 113 75.84
CD4 Count done
Yes 36 24.16
Not applicable 113 75.84
CD4 Count
≥200 cells/mm3 32 88.89
<200 cells/mm3 4 11.11
Patient is on treatment for HIV
Yes 23 63.89
No 13 36.11
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Chest X-ray
The Chest X-ray result was available on admission to hospital 149(100%), The Chest X-ray
result on admission to hospital revealed with no lung cavity 32(21.48%), With Lung cavity
117(78.52.5%), Chest X-ray which revealed Pulmonary Tuberculosis with pleural effusion
23(15.44%), no pleural effusion 126(84.56%), Chest X-ray result which revealed Pulmonary
Tuberculosis without Pneumonia 147(98.7%), not known 2(1.3%). See Table 2
Table 2   Presence of Cavity on Chest X-Ray of MDR-TB Patients treated in St. Peter TB-
Specialized Hospital Addis Ababa, Ethiopia 2011
Chest X-ray result #                      %
Chest X-ray result on admission
Available 149 100
Chest X-ray result on admission revealed
No Lung Cavity 32 21.48
With Lung Cavity 117 78.52
Chest X-ray on admission Shows P.TB with Pleural Effusion
Yes 23 15.44
No 126 84.56
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Bacteriology
Sputum smear result on admission was positive 144(96.6%), negative 5(3.36%), smear result on
the first month after initiation of MDR-TB treatment was positive 42(28.19%), and negative 107
(71.81%). Sputum smear result on the second month after initiation of MDR-TB treatment was
positive 16(10.74%), negative 133(89.26%). Sputum smear result on the third month after
initiation of MDR-TB treatment was positive 6(4.03%), negative 143(95.97%). Culture result on
admission was positive 144(96.64%) and negative 5(3.36%). Culture result on the first month
after initiation of MDR-TB treatment was positive 126(84.56%), negative 23(15.44%). The
Culture result on the second month after initiation of MDR-TB treatment was positive
76(51.01%), negative 73(48.99. Culture result on the third month after initiation of MDR-TB
treatment was positive 26(17.45%), negative 123(82.55%). The culture and sensitivity result on
admission was available 149(100%), the culture and sensitivity result on admission revealed
resistant to INH and Rifampicin 33(22.15%), resistant to INH, Rifampicin and others
116(77.85%), Sputum smear conversion revealed early conversion (Sputum smear which was
positive on admission converts to negative in three or less than three months) 138(92.62%), late
conversion(Sputum smear which was positive on admission still remains positive at the end of
third month)  11(7.38%). Culture conversion revealed early conversion (Culture which was
positive on admission converts to negative in three or less than three months) 118(79.19%), Late
conversion (Culture which was positive on admission still remains positive at the end of third
month) 31(20.81%),  (Table3)
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Table 3 Sputum smear and culture Conversion of MDR TB patients on second line treatment at
St. Peters Specialized Hospital in Addis Ababa, Ethiopia, June, 2011.
Culture and sputum smear results On  admission
#(%)
Month 1
# (%)
Month 2
# (%)
Month 3
# (%)
Sputum Smear
- Positive
- Negative
144(96.6)
5(3.36)
42(28.19)
107(71.81)
16(10.7
4)
133(89.
26)
6(4.03)
143(95.9
7)
Culture result
- Positive
144(96.6) 126(84.6) 76(51.0
1)
26(17.45)
- Negative 5(3.36) 23(15.44) 73(48.9
9)
123(82.5
5)
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Table4
Adjusted Factors associated with culture conversion in MDR TB patients on second line anti-TB
treatment St. Peter TB-Specialized, Addis Ababa, June 2011
Culture early
converter
Culture Non-
converters
COR(95%
C
AOR   (95%
CI)
Sex
Female
Male
65(82.3%)
58(82.9%)
14(17.7%)
12(17.1%)
1.0
0.96(.41-
2.24)
0.77(0.28-
2.13)
Age group
≤24 years
25-34-
≥35-
48(90.6%)
47(81.01%)
28(73.7%)
5(9.4%)
11(19.0%)
10(26.3%)
3.43(1.06-
11.05)
1.53(.58-4.05)
1.0
0.79(.23-
2.75)
0.93(.24-
3.86)
Weight at
admission
≤40 Kg
40-50Kg
>50Kg
25(86.2%)
54(78.3%)
44(86.3%)
4(13.8%)
15(21.7%)
7(13.7%)
0.58(.17-1.91)
1.01(0.27-
3.78)
1.0
HIV status
-Positive
-negative
104(92.0%)
19(52.8%)
9(8.0%)
17(47.2%)
10.34(4.02-
26.59)
1.0
0.90(0.03-
0.29)
pleural
effusion
- Present
-absent 16(69.6%)
107(84.9%)
7(30.4%)
19(52.8)
0.41(0.15-
1.12)
1.0
1.82(.56-
5.92)
History of Rx
with Cat II
Rx
-Yes
-No
3(75.0%)
120(82.8%)
1(25.0%)
25(17.2%)
1.0
0.63(0.06-
6.26)
Contact  with
TB case
-Yes
-No 72(80.0%)
51(86.4%)
18(20.0%)
8(13.6%)
1.0
0.62(.25-1.55) 1.79(0.64-
5.04)
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Taking the early convertors as reference; the Culture conversion in the third month for HIV
positives, revealed 104(92.0%) with OR 10.34(4.02-26.59).This is very significant and it shows
that HIV-positives are converting ten times slower than the HIV negatives; that is HIV negatives
are early convertors.
The culture conversion in the third month for age group ≤ 24 years revealed 48(90.6%) with
OR3.43 (1.06-11.05) and P .039. This is also significant and it indicates that the young (age≤ 24)
are the early convertors.
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DISCUSSION
Almost 95% sputum smear converted and 82% culture converted on the third month of MDR
treatment Therefore, the majority of our patients can be considered early converters to the
treatment which has significant implication to the TB program in terms of further prevention of
spread of MDR TB cases and prevention of XDR TB.  It indicates that patients did not have
exposure to the second lines drugs. It also has an implication in terms of the bed occupancy rate;
however, this has to be given serious consideration since this high rate of conversion wouldn’t
have been achieved had it not been for strict observed treatment in admitted patients.  When we
compare ours with the retrospective study done in Latvia in 2000; ours is very good and
encouraging in terms of treatment response.
The early converters are the young [OR3.43 (1.06-11.05) and P .039] and the HIV positives are
the late convertors [104(92.0%) with OR 10.34(4.02-26.59)]. This may be due to their
immunological status, as the young and those without HIV have better immunological status
which can synergize the effect of the treatment. Those who are HIV-positive are the late
convertors and our study has similar results when compared with the retrospective cohort study
of patients in HIV-prevalence settings in the Lesotho national MDR-TB program.
As St Peter TB-Specialized Hospital is the only MDR-TB treatment center for the whole country
(recently the Gondar MDR-treating center is added), currently only few patients could get the
chance to treatment and the remaining majority is still outside spreading the diseases, therefore,
it is good to know who the early converters are. If there is a decision to plan for outpatient
observed treatment it can focus on the young and the HIV negatives.
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Among the 149(100%) participants who were included in the final analysis 125(83.9%) were
residents Addis Ababa and the rest were from other Administrative Regions. This could be
because they have access to the treatment centre and one cannot conclude the number of MDR
cases is higher in Addis Ababa than in regions. Nevertheless, it is important to note that a large
number of MDR TB cases are living in this city which is very alarming to the TB control
program as the city is densely populated and is a place for many international offices. It also calls
to assess the situation in the rest of the regions.
The sputum smear conversion in the first month after the start of anti-TB treatment for MDR-TB
is 107 (71.81%). This is very high and different than what we observe in other literatures. This
also need further study to identify what other possible reasons exist. Even though the culture
conversion rate is not as high as the sputum smear conversion; we can see that the culture
conversion at the end of third month is 123(82.55%). This is also very high result when
compared with other literatures. This would also indicate that the patients did not have exposure
to the second lines drugs.
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Strength of the study
 This study is the first systematic evaluation since the start of MDR-TB treatment in the
country
 Data was collected by the Nurses who are assigned in the MDR-TB ward who knows
very well the documentation and archiving system of the hospital and this ensures the
data quality
 After the data was collected by the data enumerator nurses data verification was carried
out by the supervisors (physicians) working in the MDR-TB ward and final verification
was done by the Principal Investigator; all these also ensures the data quality additionally.
Limitations of the Study
 We rely only on the available information.  According to literatures diseases like
Diabetes and Hypertension are very important factors for the delay of sputum smear and
also culture conversion. These important factors were not documented in the patients’
chart. Therefore, we were not able to do analysis and report if these diseases were also
factors for delay of conversion in our study.
 History of previous treatment; Place of treatment (Hospital, H/center, Private Clinic
etc…) was not documented in patient’s chart and we were not able to identify in which
place was MDR-TB significant.
 Defaulters are prone to develop drug resistance. In this study the history of treatment
default was also not documented in the patients’ chart; so we were not able to comment if
history of default has contributed to the development of Drug Resistant-TB.

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Conclusion
 Sputum early convertors are 92.62% and Culture early convertors are 79.19%.These
reveal good treatment response and could predict high cure rate.
 The Study confirmed that > 92% of MDR patients convert their culture in ≤ 3/12:
- This could minimize the hospital stay of the patients which currently extend up to 6/12;
- It would increase the turn-over;
- This in-turn would increase the number of patients to be treated
- And finally minimize MDR-TB load of the country
 As St Peter TB-Specialized Hospital is the only MDR-TB treatment center for the whole
country, (recently the Gondar MDR-treating center is added), currently only few patients
could get the chance to treatment and the remaining majority is still outside spreading the
disease, therefore, it is important knowing who the early converters are in order to utilize
efficiently the limited hospital service.
 If there is a decision to plan for outpatient observed treatment we can consider/ focus on :
-The young and
- The HIV negatives
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RECOMMENDATIONS
For Policy makers:
 Ambulatory DOTS can be considered for MDR patients after 3 months of optimal stay in
the hospital.
 Encourage referrals from other administrative regions for MDR-TB Rx.
 Give Special attention to the elderly and HIV-positives
For program managers and health facility implementers:
 Important to improve the recording of patients’ information as it is needed to evaluate the
treatment program
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ANNEX I
DATA COMPILATION FORM
DATA SOURCE: Patient’s Medical record
(I) Patient’s Card number        /……/……/……/……/……/……/
(II) Patient’s Cod number       /……/……/……/
(III) Date of Admission    day/……/……/month/……/……/year/……/……/……/……/
(IV) Address.      (1)  Addis Ababa       (2) Other administrative region     /……/
(V) Age……………………………………………………………. /……/……/ Years
(VI) Sex………….. (1)  Female          (2) Male…………………………/……/
(VII) Weight on Admission for MDR-TB treatment …………. /……/……/ Kg
(VIII) Weight after two months of MDR-TB treatment ……. /……/……/ Kg
(IX) Sputum Smear result on admission for MDR-TB treatment
(1) Positive (2) negative    (3) Contaminated    (4) not available   /……/
(X) Sputum Smear result at first month after MDR-TB treatment
(1) Positive    (2) negative   (3) Contaminated (4) not available /……/
(XI) Sputum Smear result at second month after MDR-TB treatment
(1) Positive   (2) negative    (3) Contaminated (4) not available   /……/
(XII) Sputum Smear result at third month after MDR-TB treatment
(1) Positive (2) negative     (3) Contaminated (4) not available   /……/
(XIII) A. Culture result on admission for MDR-TB treatment
(1) Positive (2) negative     (3) contaminated (4) not available   /……/
(XIV) Culture result at first month after MDR-TB treatment
(1) positive    (2) negative       (3) Contaminated   (4) not available   /……/
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(XV) Culture result at second month after MDR-TB treatment
(1) positive    (2) negative (3) Contaminated (4) not available…… /……/
(XVI) Culture result at third month after MDR-TB treatment
(1) positive    (2) negative (3) Contaminated (4) not available……………..…../……/
(XVII) Culture and sensitivity result on admission for MDR-TB treatment
(1) available              (2) not available…………………………………………./……/
(XVIII) Culture and sensitivity result on admission for MDR-TB is resistant to
(1) INH    (2) RIF (3) INH & RIF (4) INH & RIF Plus others.…..……………/……/
(XIX) Previously treated with Category-I anti-TB drugs
(1) Yes   (2) no (3) Not known……………………….………………………../……/
(XX) Previously treated with Category-II anti-TB
(1) Yes   (2) no (3) not known………………………………………………./……/
(XXI) Place for CAT- I of Anti-TB treatment
(1) Health center (2) Hospital (3) Not known……………….…………….../……/
(XXII) Place for CAT- II of Anti-TB treatment
(1) Health center (2) Hospital (4) Not known…….………………………../……/
(XXIII) Patient has defaulted his treatment while he/she was on CAT- I of Anti-TB treatment
(1) Yes        (2) No          (3) Not known …..……………………….. /……/
(XXIV) Patient has defaulted his treatment while he/she was on CAT-II of Anti-TB treatment
(1) Yes (2) No             (3) Not known…………………….………./……/
(XXV) Has previous History of contact with Pulmonary TB patient
(1) Yes         (2) No        (3) Not known…….………………………/……/
(XXVI) Chest X-ray result on admission for MDR TB treatment
(1) Available (2) not available………………………………………./……/
(XXVII) Chest X-ray revealed    (1) No lung cavity   (2) Left lung cavity (3) Right lung cavity
(4) bilateral lung cavities               (5) not applicable……………...………/……/
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(XXVIII) Chest X-ray revealed P.TB with pleural effusion
(1) Yes (2) No (3) not applicable……………..…………………………../……/
(XXIX) Chest X-ray revealed P.TB with Pneumonia (1) Yes (2) No (3) not applicable…/……/
(XXX) Patient is Diabetic................ (1) Yes (2) no (3) not known…………………./……/
(XXXI) Patient is on treatment for Diabetes........
(1) Yes   (2) no   (3) not applicable………………………….……………./……/
(XXXII) Patient is Hypertensive …. (1) Yes   (2) no (3) not known..…..….………./……/
(XXXIII) Patient is on treatment for hypertension
(1) Yes    (2) no (3) not applicable……………../……/
(XXXIV) HIV status…………….. (1) Positive (2) Negative (3) Not tested………/……/
(XXXV) CD4-count done              (1) Yes   (2) no   (3) not applicable……………./……/
(XXXVI) CD4-count is ………………….
(1) ≥ 200 cells/mm3 (2) < 200 cells/mm3 (3) not applicable………………./……/
(XXXVII) Patient is on treatment for HIV………..
(1) Yes   (2) no   (3) not applicable….…………. /……/
(XXXVIII) Patient was on treatment for any other disease other than Diabetes, Hypertension or
HIV…………………………… (1) Yes   (2) No (3) Not known………………../……/
Completed by: Name …………………………………………………………
Signature: ……………… Day/……/……/month/……/……/year/……/……/……/……/
Checked by:  Name…………………………………………………………
Signature: ………………………………………………………
Day/……/……/month/……/……/year/……/……/……/……/
Verified by: Name…………………………………………………………..
Signature………………………………
Day/……/……/month/……/……/year/……/……/……/……/
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ANNEX II
CONSENT FORM
Since this research is a retrospective study, we do not have any contact with the patients. The
base-line demographic characteristics and all important information are collected from the
available medical records; treatment charts; bacteriologic laboratory records and chest x-ray
results. Therefore, we do not have the need for consent papers.
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